<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Coupon More | Thompson Cooley | Aktivität</title>
	<link>https://coupon-more.com/members/soytrip51/activity/</link>
	<atom:link href="https://coupon-more.com/members/soytrip51/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Aktivitäts-Feed für Thompson Cooley.</description>
	<lastBuildDate>Tue, 07 Apr 2026 15:16:23 +0200</lastBuildDate>
	<generator>https://buddypress.org/?v=</generator>
	<language>de</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">d8f9446cc1404e15ace0e24e93392e28</guid>
				<title>Thompson Cooley postete ein Update: The present study sought to investigate the effect of [&#133;]</title>
				<link>https://coupon-more.com/activity/p/68820/</link>
				<pubDate>Sat, 28 Sep 2024 07:26:27 +0200</pubDate>

									<content:encoded><![CDATA[<p>The present study sought to investigate the effect of micronized resveratrol supplementation on serum levels of asymmetric de-methyl-arginine (ADMA) and paraoxonase-1 (PON1) activity in patients with type 2 diabetes (T2D). <a href="https://www.selleckchem.com/products/SU11274.html" rel="nofollow ugc">selleckchem</a> In this double-blinded randomized trial, 76 patients with T2D were recruited. Participants were randomly assigned&hellip;<span class="activity-read-more" id="activity-read-more-68820"><a href="https://coupon-more.com/activity/p/68820/" rel="nofollow ugc">[Weiterlesen]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e400752f96f308f61328aa095f99d66d</guid>
				<title>Thompson Cooley postete ein Update: This &quot;from drug discovery to drug delivery&quot; methodology [&#133;]</title>
				<link>https://coupon-more.com/activity/p/68390/</link>
				<pubDate>Wed, 25 Sep 2024 07:26:28 +0200</pubDate>

									<content:encoded><![CDATA[<p>This &#8222;from drug discovery to drug delivery&#8220; methodology provides a potential therapeutic strategy using the liposomal 9-AA, the NR4A1 activator to suppress neuroinflammation for treatment of ischemic stroke.A novel strategy to construct the highly oxidized 3-oxabicyclo[3.3.0]octane skeleton was developed via a gold-catalyzed cascade cyclization&hellip;<span class="activity-read-more" id="activity-read-more-68390"><a href="https://coupon-more.com/activity/p/68390/" rel="nofollow ugc">[Weiterlesen]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">9cde0f1ca6c5f177204d71708a780c44</guid>
				<title>Thompson Cooley postete ein Update: Furthermore, we try to argue why research into some diseases [&#133;]</title>
				<link>https://coupon-more.com/activity/p/64200/</link>
				<pubDate>Wed, 18 Sep 2024 18:44:45 +0200</pubDate>

									<content:encoded><![CDATA[<p>Furthermore, we try to argue why research into some diseases is prioritized, and why other diseases are underrepresented in current Austrian research. While spatiotemporal indicators could not be assessed due to the variability in methodologies and objectives of various studies, the information provided by this review offers the first&hellip;<span class="activity-read-more" id="activity-read-more-64200"><a href="https://coupon-more.com/activity/p/64200/" rel="nofollow ugc">[Weiterlesen]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">6797c9f618b34d2e00760ef475da618f</guid>
				<title>Thompson Cooley wurde ein Mitglied</title>
				<link>https://coupon-more.com/activity/p/64095/</link>
				<pubDate>Wed, 18 Sep 2024 18:24:03 +0200</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>